Drug Discovery and Chemical Biology Consortium
The Drug Discovery and Chemical Biology (DDCB) Consortium is a Biocenter Finland -funded national research infrastructure for academic researchers in Finland.
DDCB coordinates infrastructure and expertise in the areas of drug discovery and chemical biology, and makes it available to the scientific community. It is formed by Institute for Molecular Medicine Finland (University of Helsinki, UH), Biocenter Kuopio (University of Eastern Finland, UEF), Faculty of Pharmacy at the University of Helsinki, BioCity Turku (University of Turku and Åbo Academy University) and CSC – IT Center for Science. The principal investigator of the DDCB consortium is Dr. Päivi Tammela (UH).
In 2017, DDCB services were used by 134 research groups, of which 9 were non-academic. Several new technologies have been utilized, and DDCB has participated actively in European activities such as EU-OPENSCREEN.
Expertise and services provided
The DDCB expertise includes drug discovery & chemical biology, assay development, high throughput screening (HTS), high content screening (HCS), virtual screening (VS), molecular modeling, chemoinformatics and ADMET studies.
Libraries and infrastructure
DDCB maintains and offers state-of-the-art instrumentation for low-, medium- and high-throughput screening and high content screening. It provides access to a shared small molecule collection of over 140 000 drugs and drug-like compounds that are ready to use for screening, and computing and software for virtual screening and molecular modeling.
Pricing and Access Policy
DDCB operates with an open access first-come first-served policy. Biocenter Finland funding allows the DDCB to drastically subsidize the costs of the services offered. The user pays for material and reagent costs, for access to the specialty equipment and materials (such as the libraries) and in the cases where it’s needed, a small portion of the staff support.
Links to international networks
DDCB links closely to the Nordic Chemical Biology community and EU-OPENSCREEN, focusing on the development of bioactive molecules.